` Patent No. 7,765,107
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`
`
`
`
`
`PAR PHARMACEUTICAL, INC., WOCKHARDT BIO AG, and
`AMNEAL PHARMACEUTICALS LLC,
`Petitioners,
`
`v.
`
`JAZZ PHARMACEUTICALS, INC.,
`Patent Owner.
`
`_____________________
`
`Case IPR2015-005471
`Patent 7,765,107
`_____________________
`
`PETITIONERS PAR PHARMACEUTICAL, INC.’S AND
`AMNEAL PHARMACEUTICALS LLC’s
`REQUEST FOR ORAL ARGUMENT
`
`
`
`
`
`
`
`Mail Stop “PATENT BOARD”
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`1 Case IPR2015-01820 has been joined with this proceeding.
`
`
`
`Pursuant to 37 C.F.R. § 42.70(a) and the Scheduling Order entered on July
`
`IPR2015-00547
` Patent No. 7,765,107
`
`
`
`28, 2015, Petitioners Par Pharmaceutical, Inc. and Amneal Pharmaceuticals LLC
`
`respectfully request oral argument on April 19, 2016. Petitioners propose that the
`
`Board conduct a consolidated proceeding in Inter Partes Review Nos. IPR2015-
`
`00545, -00546, -00547, -00548, -00551, and -00554, as well as any matters joined
`
`therewith, as these cases all are scheduled for hearing on the same date, relate to
`
`the same patent family, and the challenge is on identical art (with the exception of
`
`two of the claims in IPR2015-00551, which are instituted on a separate ground that
`
`includes the identical art with an additional reference).
`
`For these proceedings, Petitioners respectfully request a total of ninety (90)
`
`minutes to present its arguments, including time to be reserved for rebuttal, and
`
`proposes that Patent Owner have a total of ninety (90) minutes to present its
`
`responsive arguments.
`
`The parties will exchange demonstrative exhibits five (5) business days in
`
`advance of the oral hearing in accordance with 37 C.F.R. § 42.70(b). The parties
`
`have agreed to exchange one set of demonstratives addressing issues in all six of
`
`IPR2015-00545, -00546, -00547, -00548, -00551, and -00554 (and any joined
`
`proceedings) per side, and that any references to exhibits and papers will be made
`
`to the exhibits and papers filed in IPR2015-00548 for issues common across all
`
`
`
`
`IPRs, except that references to other proceedings’ pleadings and exhibits may be
`
`IPR2015-00547
` Patent No. 7,765,107
`
`made only when necessary to address issues specific to those proceedings.
`
`Without waiving any issue not specifically listed below, Petitioners identify
`
`the following issues to be argued at the April 19, 2016 hearing:
`
`1) Whether the Advisory Committee Art (“ACA”) was publicly available
`
`more than one year before December 17, 2002;
`
`2)
`
`The construction of the following claim terms:
`
`a. “determining with the computer processor … patterns of potential
`
`prescription abuse … from periodic reports generated only by the
`
`central database,”
`
`b. “wherein said [prescription] request data contain information
`
`identifying the patient,” and
`
`c. “wherein said [prescription] request data contain information
`
`identifying … credentials of the medical doctor.”
`
`3)
`
`The obviousness of claims 1-6 of the 7,765,107 patent over the ACA,
`
`including, but not limited to:
`
`a. Whether the ACA disclosed, taught, or suggested the claimed
`
`prescription request; and
`
`b. Whether the ACA disclosed, taught, or suggested the claimed
`
`periodic reports.
`
`
`
`2. Arguments and evidence presented in any motions to exclude
`
`IPR2015-00547
` Patent No. 7,765,107
`
`
`
`evidence or response thereto.
`
`3.
`
`Any other issues that the Board deems necessary to issue a final
`
`written decision.
`
`Petitioners
`
`request
`
`the use of audio/visual equipment
`
`to display
`
`demonstrative exhibits, including the use of a computer, projector, and screen. In
`
`accordance with Trial Practice Guide, 77 Fed. Reg. at 48768, Petitioners will work
`
`to discuss this request with the Board Trial Division.
`
`
`
`
`
`
`
`IPR2015-00547
` Patent No. 7,765,107
`
`Respectfully Submitted,
`
`
`
`
`
`
`
`Matthew C. Ruedy (Reg. No. 64,823)
`Maddox Edwards, P.L.L.C.
`1900 K Street NW – Suite 725
`Washington, D.C. 20006
`(202) 830-0779
`mruedy@meiplaw.com
`
`Attorney for Petitioners Amneal
`Pharmaceuticals LLC and Par
`Pharmaceutical, Inc.
`
`
`
`
`
`Date: March 18, 2016
`
`
`
`
`
`CERTIFICATION OF SERVICE (37 C.F.R. §§ 42.6(e))
`
`IPR2015-00547
` Patent No. 7,765,107
`Certificate of Service
`
`
`The undersigned hereby certifies that the above-captioned “Petitioners Par
`
`Pharmaceutical, Inc.’s and Amneal Pharmaceuticals LLC’s Request for Oral
`
`Argument” was served in its entirety on March 18, 2016, upon the following
`
`parties via e-mail:
`
`F. Dominic Cerrito
`nickcerrito@quinnemanuel.com
`Eric C. Stops
`ericstops@quinnemanuel.com
`Evangeline Shih
`evangelineshih@quinnemanuel.com
`Frank Calvosa
`frankcalvosa@quinnemanuel.com
`QUINN EMANUEL URQUHART &
`SULLIVAN LLP
`51 Madison Avenue
`22nd Floor
`New York, NY 10010
`Counsel for Patent Owner Jazz
`Pharmaceuticals, Inc.
`
`Patrick C. Gallagher
`PCGallagher@duanemorris.com
`DUANE MORRIS LLP
`190 South LaSalle Street, Suite
`3700
`Chicago, IL 60603-3433
`Counsel for Petitioner Wockhardt Bio
`AG
`
`
`
`
`
`
`John V. Biernacki
`jvbiernacki@jonesday.com
`JONES DAY
`North Point
`901 Lakeside Avenue
`Cleveland, OH 44114
`
`
`
`
`Jordana Garallek
`JGarallek@duanemorris.com
`DUANE MORRIS LLP
`1540 Broadway
`New York, NY 10036-4086
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-00547
` Patent No. 7,765,107
`Certificate of Service
`
`
`Respectfully Submitted,
`
`
`
`
`
`
`
`Matthew C. Ruedy (Reg. No. 64,823)
`Maddox Edwards, P.L.L.C.
`1900 K Street NW – Suite 725
`Washington, D.C. 20006
`(202) 830-0779
`mruedy@meiplaw.com
`
`Attorney for Petitioners Amneal
`Pharmaceuticals LLC and Par
`Pharmaceutical, Inc.
`
`
`
`Date: March 18, 2016